Incidence, prevalence and outcome of extensive virologic failure in over 60,000 patients with HIV (PLATO ll)

超过 60,000 名 HIV 患者广泛病毒学失败的发生率、患病率和结果 (PLATO ll)

• 批准号: G0700832/1
• 负责人: Andrew Phillips
• 金额: $ 68.47万
• 依托单位: University College London
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2008
• 资助国家: 英国
• 起止时间: 2008 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=G0700832%2F1
• 关键词: Incidence; prevalence; outcome; extensive; virologic

Over 40 million people in the world have HIV infection. Around 2.5 million are being given drugs to combat the infection. More and more people are being given these drugs, particularly in Africa where the proportion of people with HIV is very high. When taken in combination these drugs are effective at stopping the HIV virus from reproducing itself in a person?s body. When this happens people with HIV tend to get better and are at less risk of getting sick with an AIDS disease. Unfortunately, however, some drugs lose their benefit because the virus develops resistance to them. When this happens, doctors will change the drugs to ones that should still work. So far, the drugs we have available mainly belong to one of three classes. Some patients have reached a point where they have used up all the drugs and there are no drugs left in these three classes that are effective against their virus. While we know this happens, we don?t know how rapidly. This is important for us to understand, particularly because people with HIV in Africa and other developing countries do not have access to any drugs apart from these. Patients who have no more drugs available to control their virus will eventually develop AIDS and die. In developed countries like the UK, we have three newer drug classes available. This means that the people who have failed the original drugs may still have drug options left to control their virus. But we do not know much about these drugs as they are very new. It is likely that the virus will often eventually become resistant to these new drugs also. At that point patients in developed countries would also be in severe danger of AIDS and death. Our project will bring together data from over 60,000 people with HIV in Europe in order to examine how long it takes before all available drugs have stopped working, and what happens to patients for whom this has occurred. Besides obviously being important for doctors and their patients our research is likely to help those planning future health care services, those planning to try to develop new drugs and other researchers that are thinking of new studies to do in these kinds of patients.

世界上有4000万人感染了艾滋病毒。大约有250万名药物与感染作斗争。越来越多的人得到了这些药物，尤其是在非洲，艾滋病毒患者比例很高的非洲。合并时，这些药物有效地阻止了艾滋病毒在人体中繁殖自身。发生这种情况时，患有艾滋病毒的人会变得更好，并且患有艾滋病疾病生病的风险较小。然而，不幸的是，某些药物失去了好处，因为该病毒会对它们产生抗药性。发生这种情况时，医生会将这些药物更改为应该工作的药物。到目前为止，我们提供的药物主要属于三个类别之一。一些患者已经达到了所有药物的用处，而这三个类别中没有药物有效地针对其病毒。虽然我们知道这种情况发生了，但我们不知道有多迅速。这对我们来说很重要，尤其是因为非洲和其他发展中国家艾滋病毒的人除此之外没有任何药物。没有更多药物可以控制病毒的患者最终会发展艾滋病并死亡。在像英国这样的发达国家中，我们提供了三个较新的药品类别。这意味着原始药物失败的人可能仍然有药物选择来控制其病毒。但是我们对这些药物的了解并不多，因为它们是非常新的。该病毒最终可能最终也会对这些新药有抵抗力。那时，发达国家的患者也将面临艾滋病和死亡的严重危险。我们的项目将汇总来自欧洲60,000多人的艾滋病毒患者的数据，以检查所有可用药物停止工作需要多长时间，以及发生这种情况的患者会发生什么。除了显然对医生及其患者非常重要的是，我们的研究可能会帮助计划未来的医疗服务，那些计划试图开发新药和其他正在考虑在此类患者中进行新研究的研究人员。